Journal: Cancer Cell International
Article Title: Mithramycin targets head and neck cancer stem cells by inhibiting Sp1 and UFMylation
doi: 10.1186/s12935-024-03609-6
Figure Lengend Snippet: The UFM1 expression is increased in tumor spheres and associated with their size and stemness. The expression and colocalization of UFM1 in adherent cells and tumor spheres treated with poly (I: C) or poly (A: U); * p > 0.05, ** p > 0.03, ** p > 0.01 (compared to adherent cells) (Fig. 5a). Tumor spheres size in cells transfected with control siRNA and those transfected with UFM1 siRNA; * p > 0,05, ** p > 0,01, *** p > 0,005 (compared to control siRNA) (Fig. 5b). The expression of UFM1 after the siRNA silencing shown by western blot (Fig. 5c). The survival of UFM1-silenced tumor spheres (Fig. 5d). The expression of UFM1, OCT4, CD133, ABCG2, fibronectin, and vimentin after UFM1 silencing shown by qPCR; * p > 0.05, ** p > 0.03, *** p > 0.01, **** p > 0,001 (compared to control siRNA) (Fig. 5e). Immunocytochemistry shows reduced expression of CD133 and ALDH1 after UFM1 silencing; * p > 0.05, ** p > 0.03, *** p > 0.005 (compared to control siRNA) (Fig. 5f). Co-localization of CD133 and ALDH1 with UFM1 in untreated tumor spheres (Fig. 5g)
Article Snippet: Double-stranded small interfering RNA (siRNA) for knocking down the endogenous TLR3 (sc-36685), and UFM1 (sc-76804) including scrambled-sequence (control) siRNA (control siRNA-A, sc-37007), were obtained from Santa Cruz Biotechnology.
Techniques: Expressing, Transfection, Control, Western Blot, Immunocytochemistry